has sponsored live events, journal education, and internet-based CME activities and has awarded more than 80,000 hours of CME credit.Early View from The Oncologist
- Assessing the quality of care delivered to transgender and gender diverse cancer patients in Ireland; a case series
- Edmonton Symptom Assessment Scale time duration of self‐completion versus assisted‐completion in advanced cancer patients: a randomized comparison
- An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)
- Through the Virtual Looking Glass
- Molecular Profiling of Exceptional Responders to Cancer Therapy
- Standardized Supportive Care Documentation Improves Safety of High‐Dose Methotrexate Treatment
- Phase I Dose‐Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
- A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR‐Positive, HER2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy
- Apatinib in Combination with S‐1 as First‐Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single‐Arm, Phase II Trial
- Cancer in Lockdown: Impact of the COVID‐19 Pandemic on Patients with Cancer